Health TrialsbyHealthPanel

Lifetime Endurance Exercise to Prevent Coronary Artery Disease

ConditionsCoronary Artery DiseasePhysical ActivityLifestyle
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age45-70
SponsorUniversitaire Ziekenhuizen KU Leuven

About this trial

The primary objective of the Master@Heart Trial is to investigate whether lifelong endurance exercise reduces the incidence of non-calcified plaques (both mixed and soft plaques) as compared to late-onset endurance exercise and a non-athletic lifestyle.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Initiation of endurance sports before the age of 30 years

Activities at regional, national or international level

Sports: triathlon, cycling, distance running (1500 metres and longer) and rowing

Aged 45-70 years

Disqualifiers

history of smoking (> 5 pack years)

history of diabetes

diagnosis of cardiopulmonary disorder prior to inclusion

medical treatment for arterial hypertension or hypercholesterolemia

Trial population

Cohort 1: Lifelong endurance athletes. Inclusions: Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. Cohort 2: Late-onset endurance athletes. Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. Cohort 3: Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) \>3 hours /week is allowed.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

1,800 Participants
are grouped into 3 trial groups
Group A: Lifelong Endurance Athletes
Group B: Late-onset Endurance Athletes
Group C: Healthy Non-athletes

Trial outcomes

Primary outcomes

1

Incidence of Non-calcified Plaques

Incidence of non-calcified plaques (both mixed and soft plaques) assessed by Coronary CT in lifelong endurance athletes as compared to late-onset endurance athletes and non-athletic subjects.

Time frame
2 years

Secondary outcomes

1

Incidence of Atrial Fibrillation

To assess the association between the (a) amount and (b) starting age of lifelong endurance sports and atrial fibrillation assessed by Holter monitoring

Time frame
4 years
2

Prevalence of Myocardial Fibrosis

To assess the association between the (a) amount and (b) starting age of lifelong endurance sports and myocardial fibrosis assessed by cardiac magnetic resonance imaging

Time frame
2 years

Other outcomes

1

Arterial Stiffness

To assess arterial stiffness by Applanation Tonometry in lifelong endurance athletes versus late-onset athletes and non-athletic individuals.

Time frame
2 years
2

Carotid Intima Thickness

To assess carotid intima thickness by Doppler Ultrasound in lifelong endurance athletes versus late-onset athletes and non-athletic individuals.

Time frame
2 years
3

Left Ventricular Diastolic Function

To assess left ventricular diastolic function by echocardiography in lifelong endurance athletes versus late-onset athletes and non-athletic individuals.

Time frame
2 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Universitaire Ziekenhuizen KU Leuven

Lead sponsor

University Hospital, Antwerp

Collaborator

Jessa Hospital

Collaborator

Source ClinicalTrials.gov
Apply now